T-cell modulatory multimeric polypeptides and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11505591-B2
Application number	US-201716089335-A
Country	US
Kind code	B2
Filing date	May 17, 2017
Priority date	May 18, 2016
Publication date	Nov 22, 2022
Grant date	Nov 22, 2022

Abstract

The present disclosure provides T-cell modulatory multimeric polypeptides comprising two different immunomodulatory polypeptides, at least one of which is a variant immunomodulatory polypeptide. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

First claim

What is claimed is:

1. A multimeric polypeptide comprising:
a heterodimeric polypeptide comprising:
a) a first polypeptide comprising:
i) an epitope; and
ii) a first major histocompatibility complex (MHC) class I polypeptide, wherein the first MHC polypeptide is a β2-microglobulin polypeptide; and

b) a second polypeptide comprising:
i) a second MHC class I polypeptide, wherein the second MHC polypeptide is an MHC class I heavy chain polypeptide; and
ii) optionally an immunoglobulin (Ig) Fc polypeptide; and

c) at least one first immunomodulatory polypeptide, wherein the at least one first immunomodulatory polypeptide is a CD80 polypeptide, wherein the CD80 polypeptide is a wild-type CD80 polypeptide or variant thereof, wherein the CD80 polypeptide binds a CD28 polypeptide and comprises an amino acid sequence having at least 95% amino acid sequence identity to the CD80 amino acid sequence set forth in SEQ ID NO:1; and
d) at least one second immunomodulatory polypeptide, wherein the at least one second immunomodulatory is a 4-1BBL polypeptide, wherein the 4-1BBL polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the 4-1BBL amino acid sequence set forth in any one of SEQ ID NOs: 2-4, and wherein the 4-1BBL polypeptide is a variant 4-1BBL polypeptide that binds a 4-1BB polypeptide having an amino acid sequence set forth in SEQ ID NO:51 with reduced binding affinity, compared to the binding affinity of a 4-1BBL polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs: 2-4 for the 4-1BB polypeptide.

2. The multimeric polypeptide of claim 1 , wherein:
a1) the first polypeptide comprising, in order from N-terminus to C-terminus:
i) the epitope;
ii) the first MHC class I polypeptide; and
iii) at least one variant 4-1BBL polypeptide; and

b1) the second polypeptide comprising, in order from N-terminus to C-terminus:
i) at least one variant CD80 polypeptide;
ii) the second MHC class I polypeptide; and
iii) an Ig Fc polypeptide; or

a2) the first polypeptide comprising, in order from N-terminus to C-terminus:
i) the epitope;
ii) the first MHC class I polypeptide; and
iii) at least one variant CD80 polypeptide; and

b2) the second polypeptide comprising, in order from N-terminus to C-terminus:
i) at least one variant 4-1BBL polypeptide;
ii) the second MHC class I polypeptide; and
iii) an Ig Fc polypeptide,

optionally wherein one or more peptide linkers are interposed between one or more of the components of the first and/or second polypeptide.

3. A multimeric polypeptide of claim 1 , wherein the at least one first immunomodulatory polypeptide is a CD80 polypeptide comprising a wild-type amino acid sequence.

4. A multimeric polypeptide of claim 3 , wherein the CD80 polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.

5. A multimeric polypeptide of claim 1 , wherein:
a1) the first polypeptide comprises, in order from N-terminus to C-terminus:
i) the epitope;
ii) the first MHC class I polypeptide; and
iii) at least one 4-1BBL polypeptide; and

b1) the second polypeptide comprises, in order from N-terminus to C-terminus:
i) at least one CD80 polypeptide; and
ii) the second MHC polypeptide; and
iii) an Ig Fc polypeptide; or

a2) the first polypeptide comprises, in order from N-terminus to C-terminus:
i) the epitope;
ii) the first MHC polypeptide; and
iii) at least one CD80 polypeptide; and

b2) the second polypeptide comprises, in order from N-terminus to C-terminus:
i) at least one 4-1BBL polypeptide;
ii) the second MHC polypeptide; and
iii) an Ig Fc polypeptide,

wherein one or more peptide linkers are interposed between one or more of the components of the first and/or second polypeptide.

6. The multimeric polypeptide of claim 5 , comprising at least one variant CD80 polypeptide that comprises a substitution of amino acid 167, K86, or D158.

7. The multimeric polypeptide of claim 5 , comprising at least one variant 4-1BBL polypeptide that comprises a substitution of K127.

8. The multimeric polypeptide of claim 1 , comprising at least one variant CD80 polypeptide that comprises a substitution of amino acid 167, K86, or D158.

9. The multimeric polypeptide of claim 1 , comprising at least one variant 4-1BBL polypeptide that comprises a substitution of K127.

10. The multimeric polypeptide of claim 1 , wherein the at least one variant 4-1BBL polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence PAGLLDLRQG MFAQLVAQNV LLIDGPLSWY SDPGLAGVSL TGGLSYXEDT KELVVAKAGV YYVFFQLELR RVVAGEGSGS VSLALHLQPL RSAAGAAALA LTVDLPPASS EARNSAFGFQ GRLLHLSAGQ RLGVHLHTEA RARHAWQLTQ GATVLGLFRV TPEIPAGLPS PRSE (SEQ ID NO:11), wherein X is Ala, Gly, Val, Ile, Leu, Arg, His, Glu, or Asp.

11. The multimeric polypeptide of claim 1 , wherein the at least one CD80 polypeptide is a variant that comprises:
a) an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS XVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:5), where X is Ala, Gly, Val, Leu, Arg, His, Lys, Glu, or Asp; or
b) an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLX YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:7), where X is Ala, Gly, Val, Leu, Ile, Arg, His, Glu, or Asp; or
c) an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence VIHVTK EVKEVATLSC GHNVSVEELA QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE ELNAINTTVS QXPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP DN (SEQ ID NO:9), where X is Ala, Gly, Val, Leu, Ile, Arg, His, Lys, or Glu.

12. One or more nucleic acids, wherein the one or more nucleic acids individually or collectively encode the first and second polypeptides of a multimeric polypeptide according to claim 1 .

13. One or more expression vectors comprising the one or more nucleic acids of claim 12 .

14. A host cell genetically modified with the one or more expression vectors of claim 13 .

15. A composition comprising:
a) the multimeric polypeptide of claim 1 ; and
b) a pharmaceutically acceptable excipient.

16. A method of producing a multimeric polypeptide, the method comprising:
a) culturing the host cell of claim 14 in vitro in a culture medium under conditions such that the host cell synthesizes the multimeric polypeptide; and
b) isolating the multimeric polypeptide from the host cell and/or from the culture medium.

17. A method of selectively modulating the activity of an epitope-specific T cell, the method comprising contacting the T cell with the multimeric polypeptide of claim 1 , wherein said contacting selectively modulates the activity of the epitope-specific T cell.

Assignees

• Cue Biopharma Inc

Inventors

• Seidel Iii Ronald D
• Chaparro Rodolfo

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title